Results 31 to 40 of about 53,102 (149)
Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
Frontiers in Pharmacology, 2022 Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the cornerstone of the pharmacological treatment and prevention of atherothrombotic diseases.
Georges Jourdi +11 more
doaj +1 more source
ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY
Рациональная фармакотерапия в кардиологии, 2017 Current guidelines for the management of atrial fibrillation (AF) recommend using anticoagulants as first-line drugs for stroke prevention, but in real medical practice antiplatelet drugs are often prescribed to elderly patients.
E. А. Ushkalova +2 more
doaj +1 more source
Antiplatelet drugs and the perioperative period: What every urologist needs to know
Indian Journal of Urology, 2009 Antiplatelet agents like aspirin and clopidogrel are widely used for indications ranging from primary and secondary prevention of myocardial infarction or stroke to prevention of coronary stent thrombosis after percutaneous coronary interventions.
Pawan Vasudeva +4 more
doaj +1 more source
Chest, 2012 The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials.
John W, Eikelboom +4 more
openaire +3 more sources
RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE
Рациональная фармакотерапия в кардиологии, 2015 The clinical, cell and genetic factors are distinguished among reasons for resistance to antiplatelet drugs. There are many methods to detect sensitivity to antiplatelet drugs, but they all have disadvantages.
D. H. Aynetdinova +2 more
doaj +3 more sources
Reviews in Cardiovascular MedicineCoronary atherosclerosis (or coronary heart disease [CHD]) is a common cardiovascular disease that seriously damages human health. Percutaneous coronary stent implantation represents the primary treatment option for severe CHD in clinical practice ...
Ji-tong Yang +3 more
doaj +1 more source
DENTAL CONSIDERATIONS IN PATIENTS TAKING NEW ANTIPLATELET AND ANTICOAGULANT DRUGS [PDF]
Journal of IMAB, 2020 Atherosclerosis and the resulting cardiovascular and cerebrovascular diseases (myocardial infarction, coronary artery disease and stroke) are the leading cause of mortality and morbidity in the developed countries.
Atanaska S. Dinkova +2 more
doaj +1 more source
Фармация и фармакология (Пятигорск), 2021 Cardiovascular diseases (CVDs) are the leading cause of disability and mortality worldwide. Increased thrombosis is the trigger point for the development of various CVDs and their complications, and therefore, therapy with P2Y12-receptor inhibitors is ...
B. I. Kantemirova +5 more
doaj +1 more source
Antiplatelet Agents Have a Distinct Efficacy on Platelet Aggregation Induced by Infectious Bacteria
Frontiers in Pharmacology, 2020 Platelets are the cornerstone of hemostasis. However, their exaggerated aggregation induces deleterious consequences. In several diseases, such as infectious endocarditis and sepsis, the interaction between platelets and bacteria leads to platelet ...
Nadji Hannachi +9 more
doaj +1 more source
Bleeding after tooth extraction in patients receiving anticoagulation/antiplatelet therapy
口腔疾病防治, 2021 Tooth extraction in patients receiving anticoagulation/antiplatelet therapy is often considered contraindicated by many oral and maxillofacial surgeons because of a higher risk of postoperative bleeding.
HUANG Jinxia, SHI Haitao, PAN Jian
doaj +1 more source